Dr. Don Gibbons Jr, MD

• Medical Oncology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• Albert Einstein College Of Medicine

  Medical School

• Single-Cell Expression Landscape of SARS-CoV-2 ReceptorACE2and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients, 2021-03-12

• Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer, 2019-09-21

• AXL inhibition induces DNA damage and replication stress in non-small cell lung cancer cells and promotes sensitivity to ATR inhibitors, 2020-11-10

• Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer, 2021-08-19

• Cancer-associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma, 2015-12-02

• TMEM106Bdrives lung cancer metastasis by inducingTFEB-dependent lysosome synthesis and secretion of cathepsins, 2018-07-16

• Metabolic and Functional Genomic Studies Identify Deoxythymidylate Kinase as a target inLKB1Mutant Lung Cancer, 2013-05-28

• Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy, 2019-05-24

• In vivo screening identifiesGATAD2Bas a metastasis driver inKRAS-driven lung cancer, 2018-07-16

• Th17 cells contribute to combination MEK inhibitor and anti-PD-L1 therapy resistance inKRAS/p53mutant lung cancers, 2021-05-10

• A novelex vivotumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer, 2019-03-20

• Comprehensive T cell repertoire characterization of non-small cell lung cancer, 2020-01-30

• Multiplatform-based Molecular Subtypes of Non-Small Cell Lung Cancer, 2016-10-24

• Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance, 2023-06-28

• Pan-cancer survey of epithelial-mesenchymal transition markers across The Cancer Genome Atlas, 2017-05-04

• ZEB1 Induces LOXL2-Mediated Collagen Stabilization and Deposition in the Extracellular Matrix to Drive Lung Cancer Invasion and Metastasis, 2016-10-03

• Dance of The Golgi: Understanding Golgi Dynamics in Cancer Metastasis, 2022-04-28

• Image Analysis-based Assessment of PD-L1 and Tumor-Associated Immune Cells Density Supports Distinct Intratumoral Microenvironment Groups in Non-small Cell Lung Carcinoma Patients, 2016-06-01

• Immunogenomic intertumor heterogeneity across primary and metastatic sites in a patient with lung adenocarcinoma, 2022-05-11

• Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer, 2022-01-23

• Targeting DNA damage response promotes anti-tumor immunity through STING-mediated T-cell activation in small cell lung cancer, 2019-02-18

• Epithelial-mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma, 2016-02-05

• Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial, 2023-03-16

• Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer, 2017-02-15

• Metastasis is regulated via microRNA-200/ZEB1 axis control of tumor cell PD-L1 expression and intratumoral immunosuppression, 2014-10-28

• Association of Driver Oncogene Variations With Outcomes in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Chemoradiation and Consolidative Durvalumab Driver Oncogene Variations and Patients With Locally Advanced NSCLC, 2022-06-06

• MBIP (MAP3K12 binding inhibitory protein) drives NSCLC metastasis by JNK-dependent activation of MMPs, 2020-09-22

• The miR-200 family and the miR-183~96~182 cluster target Foxf2 to inhibit invasion and metastasis in lung cancers, 2015-03-23

• Regulation of ZEB1 Function and Molecular Associations in Tumor Progression and Metastasis, 2022-04-07

• The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors, 2019-12-24

• Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set, 2016-10-25

• Collagen promotes anti-PD-1/PD-L1 resistance in cancer through LAIR1-dependent CD8+T cell exhaustion, 2020-09-09

• Pan-urologic cancer genomic subtypes that transcend tissue of origin, 2017-08-04

• CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade, 2018-07-16

• Development, characterization, and applications of multi-material stereolithography bioprinting, 2021-02-04

• A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel and Nintedanib for Resectable Non-Small Cell Lung Cancer, 2020-03-19

• Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis, 2022-09-27

• CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma, 2021-01-08

• The microRNA-200/Zeb1 axis regulates ECM-dependent ß1-integrin/FAK signaling, cancer cell invasion and metastasis through CRKL, 2016-01-05

• Pan-cancer molecular classes transcending tumor lineage across 32 cancer types, multiple data platforms, and over 10,000 cases, 2018-02-09

• A collagen glucosyltransferase drives lung adenocarcinoma progression in mice, 2021-04-19

• Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis, 2023-10-01

• ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer, 2019-11-12

• Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches, 2018-06-06

• Distinct immune gene programs associated with host tumor immunity, neoadjuvant chemotherapy and chemoimmunotherapy in resectable NSCLC, 2022-06-01

• Ntrk1 Promotes Resistance to PD-1 Checkpoint Blockade in Mesenchymal Kras/p53 Mutant Lung Cancer, 2019-04-02

• Resolving the spatial and cellular architecture of lung adenocarcinoma by multi-region single-cell sequencing, 2021-05-10

• Dual inhibition of MEK and AXL targets tumor cell heterogeneity and prevents resistant outgrowth mediated by the epithelial-to-mesenchymal transition in NSCLC, 2021-01-05

• A Phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients withEGFRmutation-positive locally advanced/metastatic non-small-cell lung cancer, 2020-10-05

• CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib, 2017-05-10

• Epithelial-Mesenchymal Transition Predicts Polo-Like Kinase 1 Inhibitor-Mediated Apoptosis in Non-Small Cell Lung Cancer, 2015-11-23

• IMPAD1 and KDELR2 drive invasion and metastasis by enhancing Golgi-mediated secretion., 2020-08-04

• Phase I/II Trial of Immunotherapy with Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC: Early trial report, 2020-03-04

• miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by TargetingFlt1/VEGFR1, 2010-11-29

• Multiomics profiling of primary lung cancers and distant metastases reveals immunosuppression as a common characteristic of tumor cells with metastatic plasticity, 2020-11-04

• Local Consolidative Therapy versus Maintenance Therapy/Observation for Patients with Oligometastatic Non-Small Cell Lung Cancer without Progression after Front-Line Systemic Therapy: Results of a Multi-Institutional Phase II Randomized Study, 2016-10-24

• Neoadjuvant Chemotherapy Increases Cytotoxic T cell, Tissue Resident Memory T cell and B Cell Infiltration in Resectable Non-Small Cell Lung Cancer, 2020-10-21

• A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components, 2020-09-02

• Case Report: Immune checkpoint inhibitor-induced multiorgan vasculitis successfully treated with rituximab, 2023-07-20

• Contextual cues from cancer cells govern cancer-associated fibroblast heterogeneity, 2021-04-20

• Tumor Immunology and Immunotherapy of Non-Small-Cell Lung Cancer, 2022-05-27

• 18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer, 2020-04-16

• Gene Expression Profile of A549 Cells from Tissue of 4D Model Predicts Poor Prognosis in Lung Cancer Patients, 2013-09-03

• Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy, 2022-04-12

• ZEB1 suppression sensitizes KRAS mutant cancers to MEK inhibition by an IL17RD-dependent mechanism, 2019-03-13

• Targeting CDK4 overcomes EMT-mediated tumor heterogeneity and therapeutic resistance in KRAS-mutant lung cancer, 2021-09-08

• EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer, 2022-12-13

• STING pathway expression identifies non-small cell lung cancers with an immune-responsive phenotype, 2020-02-15

• Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma, 2022-07-17

• A patient-derived, pan-cancer EMT signature identifies global molecular alterations and immune target enrichment following epithelial to mesenchymal transition, 2015-09-29

• The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1, 2021-11-24

• Autotaxin suppresses cytotoxic T cells via LPAR5 to promote anti-PD-1 resistance in non-small cell lung cancer, 2023-09-01

• PI4KIIIß is a therapeutic target in chromosome 1q-amplified lung adenocarcinoma, 2020-01-22

• Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial, 2021-02-18

• Correction to: CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma, 2021-03-09

• Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer, 2021-11-17

• CD8+T cells inhibit metastasis and CXCL4 regulates its function, 2021-04-01

• Immunogenomic profiling of lung adenocarcinoma reveals poorly differentiated tumors are associated with an immunogenic tumor microenvironment, 2022-08-10

• Serine Proteases Enhance Immunogenic Antigen Presentation on Lung Cancer Cells, 2017-03-02

• Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer, 2023-02-08

• Smoking, p53 Mutation, and Lung Cancer, 2014-02-04